Abstract:4079 Background: About 30-50% colorectal cancer patients undergoing a curative resection will experience disease recurrence ultimately. Early detection of recurrence is of great significance for improving the prognosis of colorectal cancer patients. Circulating tumor DNA (ctDNA) has been suggested to be a promising biomarker for postoperative surveillance and prognosis prediction in various cancers including colorectal cancer. However, its performance in predicting early recurrence of colorectal cancer as well as appropriate testing procedures still needs large-scale prospective studies to evaluate. Methods: A total of 246 patients with stage II-III colorectal cancer and underwent curative resection from three clinical centers of China were enrolled in this multicenter prospective cohort study. Tissue samples as well as serial plasma samples before surgery, 7 days and 6 months after surgery and 3 months interval afterwards until recurrence were collected, and subjected to deep targeted-panel sequencing containing 425 cancer-related genes. ctDNA baseline genomic alterations and dynamic changes were analyzed. Its performance in predicting early recurrence was evaluated and compared with other clinical routine investigations, including serum biomarkers CEA and CA199, and CT examination. Results: The ctDNA positive rates at baseline (before surgery) and 7 days after surgery were 72.9% and 18.1% respectively. Among 199 patients with complete survival data, 18 patients were recurrent during follow up period with a median disease-free survival of 280.5 days (114-461 days). At baseline, high clinical stage (p = 0.035), and PTEN mutation (p = 0.009) were significantly associated with increased recurrent risk; while APC mutation (p = 0.04) predicted a decreased recurrent risk. Detection of ctDNA 7 days after surgery [HR: 5.9 (1.94-17.97); p = 0.0004] or any time point before clinical recurrence [HR: 6.14 (2.3-16.38); p < 0.0001] was associated with a significantly higher recurrent risk, and the HR increased accordingly with ctDNA mutation level. In multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathological risk factors. CEA status was not significantly (p > 0.4) associated with disease-free survival. A risk scoring model comprising of clinical variables and ctDNA detection after surgery was constructed and can predict 18-month recurrence with an AUC of 0.77. Conclusions: ctDNA is a promising marker of risk stratification, and early relapse detection in resected stage II/III CRC patients. Clinical trial information: NCT03312374 .

Usefulness of Plasma D-dimer Level for Monitoring Development of Distant Organ Metastasis in Colorectal Cancer Patients after Curative Resection

Effectiveness of D-dimer in predicting distant metastasis in colorectal cancer

D-Dimer: Not Just An Indicator Of Venous Thrombosis But A Predictor Of Asymptomatic Hematogenous Metastasis In Gastric Cancer Patients

Effectiveness of Managing Suspected Metastasis Using Plasma D-dimer Testing in Gastric Cancer Patients.

Combination of D-dimer and carcinoembryonic antigen levels as a predictive and prognostic biomarker in advanced colorectal cancer patients.

CDH3 Is an Effective Serum Biomarker of Colorectal Cancer Distant Metastasis Patients

D-Dimer and Carcinoembryonic Antigen Levels: Useful Indicators for Predicting the Tumor Stage and Postoperative Survival

Preoperative D-dimer and Gamma-Glutamyltranspeptidase Predict Major Complications and Survival in Colorectal Liver Metastases Patients after Resection

Clinical Significance of Plasma D-Dimeride Detection in Patients with Breast Cancer

Circulating Tumor DNA As a Promising Biomarker of Relapse Risk for Stage II-III Colorectal Cancer.

D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer

Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection

Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer

Plasma Levels and Clinical Significance of D-dimer in Non-Small Cell Lung Cancer Patients

The Significance of the D-Dimer Level as a Prognostic Marker for Survival and Treatment Outcomes in Patients With Stage IV Colorectal Cancer

D-dimer, a predictor of bad outcome in gastric cancer patients undergoing radical resection

Application of an Elevated Plasma D-dimer Cut-off Value Improves Prognosis Prediction of Advanced Non-Small Cell Lung Cancer

Elevated Plasma D-Dimer Level Was Correlated With Lymphatic Metastasis And Worse Outcome In Patients With Gastric Cancer

The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis

The Relationship Between D-dimer and Prognosis in the Patients with Serum Alpha-Fetoprotein-Positive Gastric Cancer: A Retrospective Cohort Study

Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: Diagnostic value for recurrent and metastatic breast cancer